Moonwalk Biosciences

Explore the latest insights on Moonwalk Biosciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Moonwalk Biosciences’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

CSPC's Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company's First Recombinant Protein Vaccine Candidate to Enter Clinical Trials
CompanyDrug

CSPC’s Recombinant Herpes Zoster Vaccine SYS6052 Clears U.S. FDA IND – Company’s First Recombinant Protein Vaccine Candidate to Enter Clinical Trials

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its Class 1 innovative drug, a recombinant herpes zoster vaccine (SYS6052), has received IND approval from the U.S. FDA to initiate clinical…

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

GenFleet's Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

GenFleet’s Oral KRAS G12D Inhibitor GFH375 Wins Third NMPA Breakthrough Therapy Designation – Combination with Cetuximab for Pretreated Metastatic Colorectal Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Moonwalk Biosciences Closes Oversubscribed USD 70 Million Series B – Eli Lilly Joins Alpha Wave and YK Bioventures to Back First‑in‑Class Adipose‑Targeted siRNA Candidate MW101